TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32284390

Group type: EXPERIMENTAL
Intervention: RCTs that explicitly described who was blinded in a trial
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: RCTs that reported any information about blinding
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Manuscripts fully reporting the status of blinding
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Discrepancies in blinding information
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Survey of authors' definitions of blinding
Number of subjects: 622
Study: 36062713

Group type: EXPERIMENTAL
Intervention: Dissociative Identity Disorder (DID)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Depressive Disorders
Number of subjects: 139
Study: 34475328

Group type: EXPERIMENTAL
Intervention: Targeting the NLRP3 inflammasome and the IL-1 pathway as a new therapeutic approach.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggressive lipid-modifying therapy combined with inflammatory modulation.
Number of subjects: 0
Study: 32951729

Group type: EXPERIMENTAL
Intervention: 5 g of baru almond oil (BG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 5 g of mineral oil (placebo, BP)
Number of subjects: 29
Study: 35872749

Group type: EXPERIMENTAL
Intervention: Heat-killed Lactiplantibacillus plantarum L-137 (HK L-137)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32758033

Group type: EXPERIMENTAL
Intervention: Cessation; cessation+exposure reduction
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Cessation+exposure reduction
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Videos
Number of subjects: 623

Group type: COMPARATOR
Intervention: No-message control
Number of subjects: 623
Study: 35628138

Group type: EXPERIMENTAL
Intervention: Diet low in AGEs
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Diet high in AGEs
Number of subjects: 70
Study: 34151710

Group type: EXPERIMENTAL
Intervention: DANBIO app
Number of subjects: 60

Group type: COMPARATOR
Intervention: Touchscreen
Number of subjects: 60
Study: 32630697

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0
Study: 33692620

Group type: EXPERIMENTAL
Intervention: Multi-domain intervention
Number of subjects: 42
Study: 34481965

Group type: EXPERIMENTAL
Intervention: Praziquantel; coverage rate of 93.51% (1990/2128)
Number of subjects: 2128

Group type: EXPERIMENTAL
Intervention: Albendazole; coverage rate of 95.25% (2027/2128)
Number of subjects: 2128

Group type: EXPERIMENTAL
Intervention: Untreated children; 31.63% (31/98) reported being unaware of the campaign; 26.53% (26/98) were unable to reach distribution points.
Number of subjects: 2128

Group type: EXPERIMENTAL
Intervention: Health workers' suggestions; increasing incentives for distribution.
Number of subjects: 2128
Study: 32961806

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 1: 120 kVp, 25 mAs
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 2: 100 kVp, 15 mAs
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 3: 120 kVp, 5 mAs
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose CT (ultra-LDCT) - group 4: 100 kVp, 5 mAs
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard CT
Number of subjects: 91
Study: 32813283

Group type: COMPARATOR
Intervention: 10-day remdesivir regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-day remdesivir regimen
Number of subjects: 0
Study: 34017122

Group type: EXPERIMENTAL
Intervention: Proinflammatory cytokines stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antitumor induction therapy
Number of subjects: 0
Study: 32354072

Group type: EXPERIMENTAL
Intervention: Bitter melon peptide (BMP) mcIRBP-19
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 142
Study: 35987467

Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam plus metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: meropenem plus placebo
Number of subjects: 0
Study: 33763656

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy plus complete mesogastric excision (D2+CME)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional D2 radical surgery
Number of subjects: 34
Study: 34599455

Group type: EXPERIMENTAL
Intervention: OptiSense lead with optimized settings
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tendril lead
Number of subjects: 110
Study: 35978334

Group type: EXPERIMENTAL
Intervention: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components (motivational counseling, nicotine replacement patches/lozenges, message framing)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Enhanced standard care (cessation advice and referral to the national Quitline) + additional tobacco treatment components
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Implementation processes (reach, fidelity, acceptability, appropriateness, sustainability, and cost)
Number of subjects: 1152
Study: 34023028

Group type: EXPERIMENTAL
Intervention: 6-month intradialytic cycling program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34906386

Group type: EXPERIMENTAL
Intervention: Autologous fat grafting (AFG) protocol with a single injection of autologous fat grafting and dressed with nano fat (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional methods of serial dressings with 1% silver sulphadiazine or other topical agents (Group B)
Number of subjects: 100
Study: 33829223

Group type: EXPERIMENTAL
Intervention: Higher dietary fiber intake in participants with the highest tertile of SCFA PGS
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Lowest tertile of SCFA PGS
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Highest tertile of SCFA PGS
Number of subjects: 424
Study: 35466952

Group type: EXPERIMENTAL
Intervention: Simvastatin for neuroprotection in PD (part of the PD STAT trial)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Qualitative insights from care partners
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Qualitative insights from research staff
Number of subjects: 235
Study: 33882225

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S (5×10^10 viral particles)
Number of subjects: 39321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39321
Study: 32538219

Group type: COMPARATOR
Intervention: Microneedling (MN) only
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined microneedling-platelet-rich plasma (MN-PRP)
Number of subjects: 40
Study: 33217833

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided deep serratus anterior plane block (Group D)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound-guided superficial serratus anterior plane block (Group S)
Number of subjects: 50
Study: 34529000

Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel plus investigational agents (graduated treatments)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Neoadjuvant paclitaxel plus investigational agents (non-graduated treatments)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Neoadjuvant paclitaxel plus chemotherapy alone (control)
Number of subjects: 938
Study: 32954969

Group type: EXPERIMENTAL
Intervention: Epsilon‐aminocaproic acid (EACA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tranexamic acid (TXA)
Number of subjects: 6
Study: 34251303

Group type: EXPERIMENTAL
Intervention: LBAL (adalimumab biosimilar candidate)
Number of subjects: 383

Group type: COMPARATOR
Intervention: adalimumab reference product (ADL)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: LBAL (after 24 weeks)
Number of subjects: 383

Group type: COMPARATOR
Intervention: ADL (after 24 weeks)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: LBAL and ADL
Number of subjects: 383
Study: 33115851

Group type: COMPARATOR
Intervention: Weekend admissions
Number of subjects: 4000
Study: 34870602

Group type: EXPERIMENTAL
Intervention: Motivation and self-regulation arm (8 modules, 17 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion regulation arm (7 modules, 17 sessions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined arm (full toolkit, 15 modules, 34 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study: 34123529

Group type: EXPERIMENTAL
Intervention: Elastic band training
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotonic training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 20
Study: 33081596

Group type: EXPERIMENTAL
Intervention: Web-based nutritional intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional face-to-face intervention
Number of subjects: 36
Study: 36018367

Group type: EXPERIMENTAL
Intervention: Cement plug (Group II)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Bone plug (Group I)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Empty canal (Group III)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 114
Study: 36348045

Group type: EXPERIMENTAL
Intervention: LE massage 3 times a week for 4 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: LE massage 2 times a week for 6 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Head/neck/shoulder massage (control) 3 times a week for 4 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Head/neck/shoulder massage (control) 2 times a week for 6 weeks
Number of subjects: 71
Study: 35717610

Group type: EXPERIMENTAL
Intervention: Smartphone-based home workout program for shift-work nurses for 18 weeks, including text-message counseling for the first 12 weeks and environmental improvement for the remaining weeks.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study: 33515745

Group type: EXPERIMENTAL
Intervention: Gore-Tex suture (2-0 Gore-Tex; W. L. Gore & Associates, Inc.)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Polydioxanone suture (2-0 polydioxanone suture)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall sexual function at 1 year
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Overall dyspareunia rates
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Age of women sexually active at 1 year
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Premenopausal status of women sexually active at 1 year
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bilateral salpingo-oophorectomy status of women sexually active at 1 year
Number of subjects: 200
Study: 32759543

Group type: EXPERIMENTAL
Intervention: Intensive therapy with 10 mg/day rosuvastatin plus 1,800 mg/day eicosapentaenoic acid (EPA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard therapy with 2.5 mg/day rosuvastatin
Number of subjects: 42
Study: 33583759

Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue/platelet-poor plasma
Number of subjects: 72

Group type: COMPARATOR
Intervention: Suction drainage
Number of subjects: 72
Study: 32812652

Group type: EXPERIMENTAL
Intervention: PIEB + PCEA (5 ml bolus every hour, 5 ml PCEA bolus lockout 20 minutes)
Number of subjects: 150

Group type: COMPARATOR
Intervention: CEI + PCEA (5 ml/h, 5 ml PCEA bolus, lockout 20 minutes)
Number of subjects: 150

Group type: COMPARATOR
Intervention: CEI + PCEA
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: PIEB + PCEA
Number of subjects: 150
Study: 36197197

Group type: EXPERIMENTAL
Intervention: Passive somatosensory stimulation along with UE motor program (Gr2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham electrical stimulation along with UE motor program (Gr1)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Comparison between Gr1 and Gr2
Number of subjects: 37
Study: 33772508

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) therapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control (adjustment of antiepileptic drugs)
Number of subjects: 227
Study: 32791671

Group type: EXPERIMENTAL
Intervention: Intranasal phototherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 40
Study: 35472141

Group type: EXPERIMENTAL
Intervention: Preoperative denosumab, curettage and adjuvant local therapy (Arm B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Curettage and adjuvant local therapy (Arm A)
Number of subjects: 18
Study: 34721377

Group type: EXPERIMENTAL
Intervention: Huayu‐Qiangshen‐Tongbi formula (HQT) plus methotrexate (MTX)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: leflunomide (LEF) plus methotrexate (MTX)
Number of subjects: 22
Study: 33090945

Group type: EXPERIMENTAL
Intervention: Grade IV posteroanterior central and unilateral Maitland mobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Grade I mobilization (Placebo)
Number of subjects: 60
Study: 32155315

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetrabenazine (25 mg)
Number of subjects: 0
Study: 34427633

Group type: EXPERIMENTAL
Intervention: Ontamalimab 75 mg every 4 weeks
Number of subjects: 268
Study: 32240350

Group type: EXPERIMENTAL
Intervention: 50% low-dose images
Number of subjects: 298

Group type: COMPARATOR
Intervention: Standard-dose images
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Low-dose images
Number of subjects: 298
Study: 35483753

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 3693
Study: 32980791

Group type: COMPARATOR
Intervention: 2D-SWE in normal pregnancies
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: 2D-SWE in A1GDM pregnancies
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: 2D-SWE in A2GDM pregnancies
Number of subjects: 259
Study: 35491524

Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg with exenatide-matched placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exenatide twice-daily 10 μg with dapagliflozin-matched placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus exenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 0
Study: 35293879

Group type: EXPERIMENTAL
Intervention: Double tear reservoir lens with 5.0-mm back optic zone diameter
Number of subjects: 65

Group type: COMPARATOR
Intervention: Euclid with 6.2-mm back optic zone diameter (aged <14 years)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Euclid with 6.2-mm back optic zone diameter (aged ≥14 years)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Double tear reservoir lens with 6.0-mm back optic zone diameter
Number of subjects: 65
Study: 32439135

Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC) for six sessions, once a week for two hours (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antenatal Usual Care (AUC) (n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antenatal Usual Care (AUC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC) and Antenatal Usual Care (AUC)
Number of subjects: 80
Study: 35689462

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine
Number of subjects: 117

Group type: COMPARATOR
Intervention: Intravesical BCG
Number of subjects: 117
Study: 33055581

Group type: EXPERIMENTAL
Intervention: Achieving protein goals within 4 days
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Failing to achieve protein goals
Number of subjects: 274
Study: 32046931

Group type: EXPERIMENTAL
Intervention: MET‐LIRA (MET-2000 mg, LIRA 1.8 mg SC QD)
Number of subjects: 153

Group type: COMPARATOR
Intervention: MET‐P (MET-2000 mg, Placebo QD)
Number of subjects: 153
Study: 35301896

Group type: EXPERIMENTAL
Intervention: ESP block group (ESP block before anesthesia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: non-ESP group (no intervention)
Number of subjects: 0
Study: 33011539

Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 343
Study: 35405248

Group type: EXPERIMENTAL
Intervention: Metformin (METF) for 2 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (CON) for 2 weeks
Number of subjects: 16
Study: 34050768

Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole (POS) prophylaxis for 7 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard-of-care only (SOC)
Number of subjects: 88
Study: 32444129

Group type: EXPERIMENTAL
Intervention: Obesity parameters (BMI, WHR, VFA)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Fat tissue parameters (BFM, FFM, VFA, TSFA, PBF)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Arterial stiffness parameters (baPWV left, baPWV right, cfPWV)
Number of subjects: 344
Study: 36330556

Group type: EXPERIMENTAL
Intervention: Stent graft (SG) and paclitaxel-coated balloon (PCB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (PCB) alone
Number of subjects: 80
Study: 33085036

Group type: EXPERIMENTAL
Intervention: Image-processing technique for assessing damage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Expert observations
Number of subjects: 50
Study: 36126857

Group type: EXPERIMENTAL
Intervention: Quality Improvement Program (QIP) implemented in 2016
Number of subjects: 1716

Group type: EXPERIMENTAL
Intervention: Quality Improvement Program (QIP)
Number of subjects: 1716

Group type: COMPARATOR
Intervention: Non-QIP (before QIP implementation)
Number of subjects: 1716
Study: 34167827

Group type: EXPERIMENTAL
Intervention: 200-mg CTC (equivalent to 112-mg celecoxib and 88-mg tramadol)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100-mg tramadol
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100-mg celecoxib
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 100-mg celecoxib plus 100-mg tramadol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 32220636

Group type: EXPERIMENTAL
Intervention: Rapid diagnosis using MALDI-TOF MS
Number of subjects: 8628
Study: 36369081

Group type: EXPERIMENTAL
Intervention: Body wash with white Marshmallow extract
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group with lukewarm water
Number of subjects: 92
Study: 32744106

Group type: EXPERIMENTAL
Intervention: Anti-PD-1/PD-L1-based therapy
Number of subjects: 8711
Study: 32783547

Group type: EXPERIMENTAL
Intervention: MTX, hydroxychloroquine plus vitamin D supplementation for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTX plus hydroxychloroquine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (30 healthy volunteers)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group II (MTX, hydroxychloroquine plus vitamin D)
Number of subjects: 40
Study: 33940337

Group type: EXPERIMENTAL
Intervention: Active tDCS over the DLPFC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 20
Study: 32336267

Group type: EXPERIMENTAL
Intervention: Medical clowning intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reference group (no medical clowning)
Number of subjects: 70
Study: 34551104

Group type: EXPERIMENTAL
Intervention: Ad5-vectored COVID-19 vaccine (5 × 10^10 viral particles)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Ad5-vectored COVID-19 vaccine (single dose)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Homologous prime-boost vaccination
Number of subjects: 430

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study: 34776151

Group type: EXPERIMENTAL
Intervention: Therapeutic Massage (TM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Positional Release Therapy (PRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 35964101

Group type: EXPERIMENTAL
Intervention: 3-month multimodal physical activity promotion/education intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no further attention)
Number of subjects: 200
Study: 33979802

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with weekly goals
Number of subjects: 30
Study: 32801651

Group type: EXPERIMENTAL
Intervention: JPI-289 35 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: JPI-289 75 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: JPI-289 150 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: JPI-289 300 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: JPI-289 450 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: JPI-289 600 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: JPI-289
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 35320359

Group type: EXPERIMENTAL
Intervention: Adjuvant osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 35997135

Group type: EXPERIMENTAL
Intervention: Wearing slippers
Number of subjects: 0

Group type: COMPARATOR
Intervention: No slippers (control)
Number of subjects: 0
Study: 34192850

Group type: EXPERIMENTAL
Intervention: Pedicled abdominal flap
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Pedicled internal hand flap
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Free tissue flap
Number of subjects: 98
Study: 32402554

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment (overall)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Overall (between 2 and 5 years)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Overall (baseline VA 20/50 to 20/320)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Overall (baseline VA 20/32 to 20/40)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Overall (CST)
Number of subjects: 463
Study: 35277669

Group type: EXPERIMENTAL
Intervention: Surgical masks (mask-on)
Number of subjects: 265

Group type: COMPARATOR
Intervention: No surgical masks (mask-off)
Number of subjects: 265